Form 4: Pham Sells Cadrenal Therapeutics Shares

Quang Pham, CEO and Chairman of Cadrenal Therapeutics, Inc., reported the sale of 1,165 shares of common stock under a Rule 10b5-1 trading plan.

Summary

• Quang Pham, who holds the positions of CEO and Chairman at Cadrenal Therapeutics, Inc., has reported a transaction involving the sale of company stock.
• The sale consisted of 1,165 shares of common stock.
• These shares were sold on May 22, 2026, at a weighted average price of $5.69.
• The transactions were executed as part of a pre-arranged Rule 10b5-1 trading plan, adopted on September 25, 2025, which is designed to comply with affirmative defense conditions.
• Following this sale, Mr. Pham directly beneficially owns 194,924 shares of common stock.
• Additionally, Mr. Pham indirectly beneficially owns 20,000 shares through The PVBQ Living Trust, where he serves as Trustee and has sole voting and dispositive power. His child is the sole beneficiary of this trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a sale by a CEO can be a negative signal, the use of a Rule 10b5-1 plan and the continued significant ownership mitigate this concern.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to stock disposition, which can mitigate concerns about insider trading.
• Mr. Pham retains a significant direct beneficial ownership of 194,924 shares and indirect ownership of 20,000 shares, suggesting continued commitment to the company.

Negatives

• The sale of company stock by a key executive, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.
• The sale involved a portion of the reporting person's holdings, reducing their direct stake in the company.

Risks

• The Rule 10b5-1 plan is subject to market conditions and the specific terms of the plan, which could lead to sales at prices that may not be optimal.
• While the plan is designed to provide an affirmative defense against insider trading allegations, any misinterpretation or misapplication of the plan's terms could lead to regulatory scrutiny.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports a past transaction.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a CEO is a common strategy to manage personal stock sales in a way that complies with regulations and avoids the appearance of trading on material non-public information. This is particularly relevant in the biotechnology sector where stock prices can be volatile.

Stakeholder Impact

• Shareholders: May interpret the sale as a sign of reduced confidence by management, although the Rule 10b5-1 plan mitigates this. Continued significant ownership by Mr. Pham should provide some reassurance.
• Employees: Similar to shareholders, employees may view insider sales with caution, but the structured nature of the sale is a mitigating factor.
• Creditors/Suppliers: Unlikely to be directly impacted by this transaction as it pertains to equity ownership.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1 plan as per its terms.
• The company may provide further updates on executive stock transactions if they occur.

Key Dates

Keywords

Cadrenal Therapeutics, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Quang Pham, CEO, Chairman, SEC Filing